MX2022015516A - Derivados de 4-etilnilpiridina útiles como inhibidores de gcn2. - Google Patents
Derivados de 4-etilnilpiridina útiles como inhibidores de gcn2.Info
- Publication number
- MX2022015516A MX2022015516A MX2022015516A MX2022015516A MX2022015516A MX 2022015516 A MX2022015516 A MX 2022015516A MX 2022015516 A MX2022015516 A MX 2022015516A MX 2022015516 A MX2022015516 A MX 2022015516A MX 2022015516 A MX2022015516 A MX 2022015516A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- ethynylpyridine
- derivatives useful
- gcn2
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención proporciona compuestos de la fórmula en donde los sustituyentes son como se exponen con mayor detalle en la especificación. Los compuestos son inhibidores potentes de GCN2 y tienen excelentes propiedades farmacocinéticas. Los compuestos son útiles para el tratamiento o prevención de una variedad de afecciones, particularmente cáncer. La invención proporciona además composiciones farmacéuticas que comprenden los compuestos de la invención y usos de los compuestos y las composiciones.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008749.0A GB202008749D0 (en) | 2020-06-09 | 2020-06-09 | Novel compounds |
| PCT/GB2021/051428 WO2021250399A1 (en) | 2020-06-09 | 2021-06-09 | 4-ethynylpyridine derivatives useful as gcn2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015516A true MX2022015516A (es) | 2023-03-22 |
Family
ID=71616023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015516A MX2022015516A (es) | 2020-06-09 | 2021-06-09 | Derivados de 4-etilnilpiridina útiles como inhibidores de gcn2. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230271939A1 (es) |
| EP (1) | EP4161915A1 (es) |
| JP (1) | JP2023529926A (es) |
| KR (1) | KR20230058042A (es) |
| CN (2) | CN119661503A (es) |
| AU (1) | AU2021289535A1 (es) |
| BR (1) | BR112022025147A2 (es) |
| CA (1) | CA3181909A1 (es) |
| GB (1) | GB202008749D0 (es) |
| IL (1) | IL298860A (es) |
| MX (1) | MX2022015516A (es) |
| WO (1) | WO2021250399A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| GB202104635D0 (en) | 2021-03-31 | 2021-05-12 | Imperial College Innovations Ltd | Methods and compositions for identifying and treating GCN2-dependent cancers |
| GB202118096D0 (en) * | 2021-12-14 | 2022-01-26 | Ip2Ipo Innovations Ltd | Novel compounds |
| GB202403113D0 (en) | 2024-03-04 | 2024-04-17 | Apollo Ap30 Ltd | Novel compounds |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037927B2 (en) | 2003-10-16 | 2006-05-02 | Abbott Laboratories | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| WO2006082371A1 (en) | 2005-02-01 | 2006-08-10 | Astrazeneca Ab | Pyrimidine compounds having tie2 (tek) inhibitory activity |
| GB0502418D0 (en) | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
| ES2679379T3 (es) | 2009-06-15 | 2018-08-24 | Nerviano Medical Sciences S.R.L. | Derivados de pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa |
| AU2012367141B2 (en) | 2012-01-28 | 2016-12-22 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives |
| JP6049768B2 (ja) | 2012-03-07 | 2016-12-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | トリアゾロピラジン誘導体 |
| WO2014031928A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| CN104870446B (zh) | 2012-11-07 | 2019-08-13 | 内尔维阿诺医学科学有限公司 | 取代的嘧啶基和吡啶基吡咯并吡啶酮类、其制备方法及其作为激酶抑制剂的用途 |
| AU2014224975B2 (en) | 2013-03-05 | 2017-09-14 | Merck Patent Gmbh | Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer |
| EP2964648B1 (en) | 2013-03-05 | 2016-11-16 | Merck Patent GmbH | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| CN105732614B (zh) | 2014-12-09 | 2018-06-12 | 中国科学院广州生物医药与健康研究院 | 磺酰胺基芳基炔类化合物及其用途 |
| CN104829613B (zh) | 2015-04-13 | 2020-06-09 | 赤峰蒙广生物科技有限公司 | 二芳基取代的吡唑并环类衍生物、其制备方法及其在医药领域的应用 |
| MA45940B1 (fr) | 2016-08-10 | 2024-12-31 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
| WO2018068739A1 (zh) | 2016-10-13 | 2018-04-19 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的炔基杂环类化合物 |
| JP7377207B2 (ja) | 2018-01-29 | 2023-11-09 | メルク パテント ゲーエムベーハー | Ｇｃｎ２阻害剤およびその使用 |
| KR20200116481A (ko) | 2018-01-29 | 2020-10-12 | 메르크 파텐트 게엠베하 | Gcn2 억제제 및 이의 용도 |
| JP2021527051A (ja) | 2018-06-05 | 2021-10-11 | ラプト・セラピューティクス・インコーポレイテッド | ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用 |
| WO2020210828A1 (en) * | 2019-04-12 | 2020-10-15 | Hibercell, Inc. | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions |
| WO2021155253A1 (en) | 2020-01-31 | 2021-08-05 | Atomwise Inc. | Anat inhibitors and methods of use thereof |
| MX2022010040A (es) | 2020-02-17 | 2022-09-05 | Alesta Therapeutics BV | Compuestos moduladores de gcn2. |
| WO2021222147A1 (en) | 2020-04-27 | 2021-11-04 | Hibercell, Inc. | Heterocyclic gcn2 modulators |
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| KR20230121758A (ko) | 2020-11-18 | 2023-08-21 | 데시페라 파마슈티칼스, 엘엘씨. | Gcn2 및 perk 키나제 억제제 및 그의 사용 방법 |
| WO2022159745A1 (en) | 2021-01-22 | 2022-07-28 | Hibercell, Inc. | Gcn2 modulating compounds and uses thereof |
| KR20240021143A (ko) | 2021-01-22 | 2024-02-16 | 히버셀, 인크. | Gcn2 조정 화합물 및 그의 용도 |
-
2020
- 2020-06-09 GB GBGB2008749.0A patent/GB202008749D0/en not_active Ceased
-
2021
- 2021-06-09 BR BR112022025147A patent/BR112022025147A2/pt unknown
- 2021-06-09 EP EP21735355.6A patent/EP4161915A1/en active Pending
- 2021-06-09 CN CN202411827368.5A patent/CN119661503A/zh active Pending
- 2021-06-09 CA CA3181909A patent/CA3181909A1/en active Pending
- 2021-06-09 IL IL298860A patent/IL298860A/en unknown
- 2021-06-09 MX MX2022015516A patent/MX2022015516A/es unknown
- 2021-06-09 CN CN202180058556.4A patent/CN116113629B/zh active Active
- 2021-06-09 WO PCT/GB2021/051428 patent/WO2021250399A1/en not_active Ceased
- 2021-06-09 AU AU2021289535A patent/AU2021289535A1/en active Pending
- 2021-06-09 KR KR1020237000394A patent/KR20230058042A/ko active Pending
- 2021-06-09 US US18/001,317 patent/US20230271939A1/en active Pending
- 2021-06-09 JP JP2022576040A patent/JP2023529926A/ja active Pending
-
2023
- 2023-03-28 US US18/191,772 patent/US11945799B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL298860A (en) | 2023-02-01 |
| WO2021250399A1 (en) | 2021-12-16 |
| BR112022025147A2 (pt) | 2023-04-25 |
| US11945799B2 (en) | 2024-04-02 |
| GB202008749D0 (en) | 2020-07-22 |
| US20230271939A1 (en) | 2023-08-31 |
| CN116113629A (zh) | 2023-05-12 |
| EP4161915A1 (en) | 2023-04-12 |
| CN116113629B (zh) | 2024-12-31 |
| CN119661503A (zh) | 2025-03-21 |
| JP2023529926A (ja) | 2023-07-12 |
| AU2021289535A1 (en) | 2023-02-09 |
| CA3181909A1 (en) | 2021-12-16 |
| US20230250082A1 (en) | 2023-08-10 |
| KR20230058042A (ko) | 2023-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015516A (es) | Derivados de 4-etilnilpiridina útiles como inhibidores de gcn2. | |
| MX2023001379A (es) | Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a. | |
| MX2024001893A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2023012726A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2024013721A (es) | Inhibidor de gcn2 | |
| GEAP202215475A (en) | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
| PH12020551305A1 (en) | Pharmaceutical Compounds | |
| MX2023012054A (es) | Inhibidor derivado heterociclico y metodo de preparacion y su aplicacion. | |
| MX2024006681A (es) | Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer. | |
| GEAP202215535A (en) | Compounds | |
| EA202091491A1 (ru) | Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1 | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| PH12018500610A1 (en) | Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity | |
| TW200833675A (en) | Nicotinamide derivatives | |
| NZ748946A (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MX2016015005A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1. | |
| MY194116A (en) | Pharmaceutical compounds | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| MX2023005039A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3. | |
| MY207787A (en) | Alpha-d-galactopyranoside derivatives | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| PH12022552177A1 (en) | Heteroaryl heterocyclic compounds and uses thereof | |
| WO2021016256A3 (en) | Ethynylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors | |
| MX2021002188A (es) | Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende. |